PMID- 29141665 OWN - NLM STAT- MEDLINE DCOM- 20180709 LR - 20220330 IS - 1478-6362 (Electronic) IS - 1478-6354 (Print) IS - 1478-6354 (Linking) VI - 19 IP - 1 DP - 2017 Nov 15 TI - Matrix metalloproteinase-3 and the 7-joint ultrasound score in the assessment of disease activity and therapeutic efficacy in patients with moderate to severe rheumatoid arthritis. PG - 250 LID - 10.1186/s13075-017-1449-z [doi] LID - 250 AB - BACKGROUND: This study aimed to investigate the reliability and validity of serum matrix metalloproteinase-3 (MMP-3) levels and articular ultrasound (US) scores in assessing disease activity and therapeutic response in rheumatoid arthritis (RA) patients. METHODS: A total of 151 RA patients were enrolled, of whom 22 were treated with certolizumab pegol (Cimzia, CZP). The RA patients were divided into the following four subgroups according to their disease activity score in 28 joints (DAS28): stable, mild activity, moderate activity, and high activity. Forty-three healthy controls were simultaneously studied. The serum MMP-3 levels and 7-joint US (US7) scores of all subjects were determined. The patients who were treated with CZP were subsequently followed for 6 months. RESULTS: The serum MMP-3 levels of all the RA patients were significantly higher than those of healthy controls, and those of patients with moderate and severe RA were significantly higher than those of patients with stable RA. The US7 scores of patients with severe RA were significantly higher than those of patients in other groups. Using the DAS28 as a reference standard, the corresponding cutoff value of MMP-3 was 70.5 ng/ml. After CZP treatment, the MMP-3 levels and US7 scores were significantly decreased at week 2, and the mean changes in US7 scores at weeks 12 and 24 were significantly higher in both groups with American College of Rheumatology 50% positive response (ACR50) and ACR 70% positive response (ACR70) than in the negative groups. CONCLUSION: Serum MMP-3 and the US7 scores could both effectively reflect disease activity and therapeutic responses in patients with moderate to severe RA. TRIAL REGISTRATION: CTR20140405 (RA0044), CTR20140405: A phase 3, Multicenter, Double-blind, Placebo Controlled, Parallel Group, Randomized, 24-Week Study to Evaluate the Safety and Efficacy of Certolizumab Pegol as Additional Medication to Methotrexate in Chinese Subjects With Active Rheumatoid Arthritis Who Have an Incomplete Response to Methotrexate, Registered on 13 June 2014. CTR20140412 (RA0078), CTR20140412: A phase 3, Multicenter, Open-label Extension Study to Assess the Safety and Efficacy of Certolizumab Pegol as Additional Medication to Methotrexate in Chinese Subjects With Active Rheumatoid Arthritis Who Participated in RA0044, Registered on 02 July 2014. FAU - Zhou, Ling AU - Zhou L AD - Department of Rheumatology and Immunology, Changzheng Hospital, Naval Medical University, 415 Fengyang Road, Shanghai, 200003, China. FAU - Wang, Geng AU - Wang G AD - Department of Rheumatology and Immunology, Changzheng Hospital, Naval Medical University, 415 Fengyang Road, Shanghai, 200003, China. FAU - Liu, Xin AU - Liu X AD - Department of Rheumatology and Immunology, Changzheng Hospital, Naval Medical University, 415 Fengyang Road, Shanghai, 200003, China. FAU - Song, Jing AU - Song J AD - Department of Rheumatology and Immunology, Changzheng Hospital, Naval Medical University, 415 Fengyang Road, Shanghai, 200003, China. FAU - Chen, Ling AU - Chen L AD - Department of Rheumatology and Immunology, Changzheng Hospital, Naval Medical University, 415 Fengyang Road, Shanghai, 200003, China. FAU - Xu, Huji AU - Xu H AD - Department of Rheumatology and Immunology, Changzheng Hospital, Naval Medical University, 415 Fengyang Road, Shanghai, 200003, China. xuhuji@smmu.edu.cn. LA - eng GR - 81273283/National Natural Science Foundation of China/ PT - Clinical Trial, Phase III PT - Journal Article PT - Multicenter Study PT - Randomized Controlled Trial DEP - 20171115 PL - England TA - Arthritis Res Ther JT - Arthritis research & therapy JID - 101154438 RN - 0 (Antirheumatic Agents) RN - EC 3.4.24.17 (MMP3 protein, human) RN - EC 3.4.24.17 (Matrix Metalloproteinase 3) RN - UMD07X179E (Certolizumab Pegol) SB - IM MH - Adult MH - Aged MH - Antirheumatic Agents/therapeutic use MH - Arthritis, Rheumatoid/blood/diagnostic imaging/*drug therapy MH - Certolizumab Pegol/*therapeutic use MH - Double-Blind Method MH - Female MH - Humans MH - Joints/*diagnostic imaging MH - Male MH - Matrix Metalloproteinase 3/*blood MH - Middle Aged MH - Severity of Illness Index MH - Treatment Outcome MH - Ultrasonography/*methods MH - Young Adult PMC - PMC5688630 OTO - NOTNLM OT - Articular ultrasonography OT - Matrix metalloproteinase-3 OT - Rheumatoid arthritis COIS- ETHICS APPROVAL AND CONSENT TO PARTICIPATE: All the recruited subjects who participated in the study had provided informed consent. The study protocol has been approved by the Medical Ethics Committee of Shanghai Changzheng Hospital (Reference number: 2014 (Ethics)-34; 2014(Ethics)-35). CONSENT FOR PUBLICATION: All authors gave final approval of the version to be published. We have obtained consent to publish from all participants to report individual patient data. COMPETING INTERESTS: The authors declare that they have no competing interests. PUBLISHER'S NOTE: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. EDAT- 2017/11/17 06:00 MHDA- 2018/07/10 06:00 PMCR- 2017/11/15 CRDT- 2017/11/17 06:00 PHST- 2017/08/16 00:00 [received] PHST- 2017/10/04 00:00 [accepted] PHST- 2017/11/17 06:00 [entrez] PHST- 2017/11/17 06:00 [pubmed] PHST- 2018/07/10 06:00 [medline] PHST- 2017/11/15 00:00 [pmc-release] AID - 10.1186/s13075-017-1449-z [pii] AID - 1449 [pii] AID - 10.1186/s13075-017-1449-z [doi] PST - epublish SO - Arthritis Res Ther. 2017 Nov 15;19(1):250. doi: 10.1186/s13075-017-1449-z.